

Attorney Docket No.

Kindly amend the claims as follows:

A 2
1. (Amended) An immortalized epithelial tumor cell with metastatic potential which has integrated in its genome or another replicative genetic element an externally introduced immortalizing oncogene which is expressed in said cell.

3. (Amended) The epithelial tumor cell according to claim 1 [or 2] which is an autologous tumor cell.

4. (Amended) The epithelial tumor cell according to [any one of claims 1 to 3] claim 1 which is a human tumor cell.

2 cont.
5. (Amended) The epithelial tumor cell according to [any one of claims 1 to 4] claim 1 which is derived from bone marrow.

6. (Amended) The epithelial tumor cell according to [any one of claims 1 to 5] claim 1, wherein said immortalizing oncogene is the DNA encoding the early region of SV40 DNA and preferably the large T antigen of a replication deficient SV40 virus.

Int B3
7. (Amended) The epithelial tumor cell according to claim 6, wherein said replication deficiency is caused by [(a) defect(s)] at least one defect in the origin of replication [and/or (a) defect(s)], at least one defect in the antigen coding region or a combination thereof.

8. (Amended) The epithelial tumor cell according to claim 6 [or 7], wherein said SV40 virus is non-infectious.

Attorney Docket No.

9. (Amended) The epithelial tumor cell according to [any one of claims 1 to 8] claim 1 which has integrated in its genome at least one additional oncogene.

11. (Amended) The epithelial tumor cell according to [any one of claims 1 to 10] claim 1, which further has [additionally] integrated in its genome or another replicative genetic element at least one externally introduced gene encoding an immunostimulatory factor.

12. (Amended) The epithelial tumor cell according to claim 11, wherein said immunostimulatory factor is B7 or a cytokine[, preferably IL-2, IL-4, IL-7, IFN- α or IFN- γ].

13. (Amended) An antibody molecule comprising an antibody or fragment thereof or a derivative of said antibody or said fragment thereof which specifically recognizes the tumor cell according to claim 1 [any one of claims 1 to 12].

14. (Amended) The [antibody or fragment thereof] antibody molecule according to claim 13, wherein said antibody or fragment thereof [which] is a monoclonal antibody or fragment thereof.

15. (Amended) The [derivative or fragment] antibody molecule according to claim 13, wherein said derivative of said antibody or fragment thereof [which] is a fusion protein, [or] a chemical conjugate, [preferably] or a bispecific antibody.

16. (Amended) An in vitro [in vitro] process for the production of the tumor cell according to [any one of claims 1 to 12] claim 1 comprising the step of

Attorney Docket No.

incorporating DNA comprising DNA encoding at least one immortalizing oncogene [and optionally at least one gene encoding an immunostimulatory factor] into a non-immortalized epithelial tumor cell with metastatic potential.

18. (Amended) The process according to claim [16 or] 17, [additionally] further comprising the step of carrying out a primary expansion of said non-immortalized epithelial tumor cells prior to the microinjection or bombardment step.

20. (Amended) The process according to claim 19, wherein said body fluid is bone marrow, blood, ascites or pleural exudate [exsudate].

21. (Amended) The process according to claim 19 [or 20], wherein said medium comprises EGF, [and/or] bFGF, or a combination thereof [preferably rh EGF and rhb FGF].

22. (Amended) The process according to [any one of claims 19 to 21] claim 19, wherein said culturing step is carried out in ECM-coated tissue flasks, [and/or] at reduced oxygen [oxygen] concentrations of 5-10%, or in ECM-coated tissue flasks at reduced oxygen concentrations of 5-10%.

Kindly add the following new claims:

--29. The epithelial tumor cell according to claim 12, wherein said cytokine is IL-2, IL-4, IL-7, IFN- α or IFN- γ .

Attorney Docket No.

30. The process according to claim 16, wherein said DNA further comprises DNA encoding at least one gene encoding an immunostimulatory factor.

31. The process according to claim 21, wherein EGF is rhEGF and bFGF is rhbFGF.

32. A diagnostic kit comprising the antibody molecule according to claim 13, in combination with means for detecting binding of said antibody molecule to said epithelial tumor cell.

33. A pharmaceutical composition comprising the epithelial tumor cell according to claim 1, or an antibody molecule selected from the group consisting of an antibody, a fragment of said antibody, a derivative of said antibody or a fragment of said derivative, wherein said antibody molecule specifically recognizes said epithelial tumor cell.

34. The pharmaceutical composition according to claim 33, wherein said composition comprises a vaccine in combination with a vaccine adjuvant.

35. A method of treating a human subject for cancer or prophylaxis of cancer comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 33 to a human subject suffering from epithelial cell cancer.

36. A method of ex vivo stimulating the immune cells of a human subject comprising treating said immune cells with an immunostimulatory amount of the epithelial tumor cells of claim 1.

H_b concavo

using a
prison
ed of
dy mol
inding
tumor

[illegible]